Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

Eli Lilly (NYSE: LLY) has been on a tear for the better part of the last decade, but the company has experienced a bit of a ...

Eli Lilly is one of the largest drug companies in the world. The pharmaceutical giant's stock price is 15% below its 2024 ...

Eli Lilly and Co. LLY has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of ...